Alligator CEO Discusses Pipeline Additions, Milestone Expectations And The IO Deal Landscape

Alligator Bioscience’s Per Norlen discusses the latest addition to its pipeline, a first-in-class bispecific tumor-localized antibody targeting the checkpoint inhibitor CTLA-4.